Ghassan Abou-Alfa, MD, MBA - New Options, Emerging Combinations in Advanced Hepatocellular Carcinoma: Are Management Approaches Poised For Transformation?
New Options, Emerging Combinations in Advanced Hepatocellular Carcinoma: Are Management Approaches Poised For Transformation? (Source: PeerView CME/CE Audio Podcast - Immunology)
Source: PeerView CME/CE Audio Podcast - Immunology - April 13, 2018 Category: Allergy & Immunology Authors: PVI, PeerView Institute for Medical Education Tags: Science, Medicine Source Type: podcasts
HOPA 2018 updates on urothelial carcinoma: what is new?
The 2018 Annual Hematology/Oncology Pharmacy Association (HOPA) Conference, held in Denver, CO, saw many thought-provoking sessions and exciting updates. Here, Kirollos Hanna, PharmD, BCOP, BCPS, of t...
Author: VJOncology
Added: 04/09/2018 (Source: Oncology Tube)
Source: Oncology Tube - April 9, 2018 Category: Cancer & Oncology Source Type: podcasts
Recommendations for the treatment of muscle and non-muscle invasive urothelial carcinoma
Speaking from the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO, Kirollos Hanna, PharmD, BCOP, BCPS, of the University of Minnesota Medical Center, Minneap...
Author: VJOncology
Added: 04/09/2018 (Source: Oncology Tube)
Source: Oncology Tube - April 9, 2018 Category: Cancer & Oncology Source Type: podcasts
Updates on immunotherapy options for metastatic urothelial carcinoma
New and exciting developments on urothelial cancer were presented at the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO. In this detailed interview, Kirollo...
Author: VJOncology
Added: 04/09/2018 (Source: Oncology Tube)
Source: Oncology Tube - April 9, 2018 Category: Cancer & Oncology Source Type: podcasts
POUT trial: a new standard of care for upper tract urothelial carcinoma
There was exciting news in the field of bladder cancer treatment at the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA. Speaking from the meeting, Alison Birtle, MRCP, FRCR, MD, of La...
Author: VJOncology
Added: 03/15/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 15, 2018 Category: Cancer & Oncology Source Type: podcasts
POUT trial: could there be a new standard of care for upper tract urothelial carcinoma?
There was exciting news in the field of bladder cancer treatment at the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA. Speaking from the meeting, Alison Birtle, MRCP, FRCR, MD, of La...
Author: VJOncology
Added: 03/15/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 15, 2018 Category: Cancer & Oncology Source Type: podcasts
Advances in Immunotherapy for GU Cancers: Focus on Renal Cell Carcinoma
Sumanta (Monty) Kumar Pal, M.D. Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research Co-director, Kidney Cancer Program, Medical Oncologist, provides an in-depth lo...
Author: moasc
Added: 03/06/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 6, 2018 Category: Cancer & Oncology Source Type: podcasts
New Guidelines for HCC: The Big Questions Tackled
Dr David Johnson provides clinicians with an overview of the new guidelines from the American Association for the Study of Liver Diseases (AASLD) on hepatocellular carcinoma. (Source: Medscape Gastroenterology Podcast)
Source: Medscape Gastroenterology Podcast - February 21, 2018 Category: Gastroenterology Authors: Medscape Source Type: podcasts
Systemic Therapy in Metastatic Renal Cell Carcinoma Antibiotic use does affect outcomes in patients
Aly-Khan Lalani, MD from Dana-Farber Cancer Institute discusses the Systemic Therapy in Metastatic Renal Cell Carcinoma Antibiotic use does affect outcomes in patients at the 2018 ASCO.
Author: Genitourinary-Cancer-Meeting
Added: 02/15/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 15, 2018 Category: Cancer & Oncology Source Type: podcasts
How do we select the urothelial carcinoma patients who will benefit from checkpoint inhibitors?
With the emergence of five novel immune checkpoint inhibitors for the treatment of urothelial carcinoma, the key question now arising is how to identify the subgroups of patients who will benefit from...
Author: VJOncology
Added: 02/09/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 9, 2018 Category: Cancer & Oncology Source Type: podcasts
Will immune checkpoint inhibitors become the new standard of care for urothelial cancer?
Immune checkpoint inhibitors for urothelial carcinoma in the relapsed/refractory setting have already been approved and are superseding standard chemotherapy. Now, there are exciting late-phase clinic...
Author: VJOncology
Added: 02/09/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 9, 2018 Category: Cancer & Oncology Source Type: podcasts
Immune checkpoint inhibitors for urothelial carcinoma: the current landscape
Novel immune checkpoint inhibitors that are entering the clinic are changing the way in which we treat metastatic urothelial carcinoma, the most common type of bladder cancer. In this interview, Thoma...
Author: VJOncology
Added: 02/09/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 9, 2018 Category: Cancer & Oncology Source Type: podcasts
Whiteboard Video: The Epidemiology of Hepatocellular Carcinoma and Current Standard of Care
Tyrosine kinase inhibitors (TKIs) are orally active, small molecules that exhibit antitumor activity by targeting enzymes that play a critical role cellular functions, including modulation of growth f...
Author: imedex
Added: 02/06/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 6, 2018 Category: Cancer & Oncology Source Type: podcasts
Velocity Vlog: Role of TKIs in Hepatocellular Carcinoma - Recent Updates
In this Velocity Vlog activity, Dr. Richard S. Finn of the UCLA Geffen School of Medicine, provides a brief overview of the epidemiology of hepatocellular carcinoma and then discusses current standar...
Author: imedex
Added: 02/06/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 6, 2018 Category: Cancer & Oncology Source Type: podcasts
The Use And Sequencing Of Tyrosine Kinase Inhibitors(TKIs) In Hepatocellular Carcinoma (HCC)
Only one TKI is approved in a first line setting. Joining us from the 2018 Gastrointestinal Cancers Symposium is Dr. Richard Kim, MD, Gastrointestinal Oncology Department, Moffitt Cancer Center, Assis...
Author: obr
Added: 01/30/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 30, 2018 Category: Cancer & Oncology Source Type: podcasts
